| March 3 |
New survey shows Michigan doctors embracing ePrescribing |
| March 3 |
Toolbar Created for PharmaLiveSearch.com, the Only Search Engine
Specific to the Pharmaceutical Industry |
| March 3 |
AEterna Zentaris and Paladin Labs Announce Sale and Purchase of
Miltefosine Rights |
| March 3 |
Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access
Novel Technology Platform |
| March 3 |
Merck Progress Report on Enrollment in Program to Resolve U.S.
Vioxx Product Liability Lawsuits |
| March 3 |
MicroDose Technologies Grants Global License to Merck & Co.,
Inc., for Use of the MicroDose Inhaler with Merck's Proprietary
Products |
| March 3 |
OneWorld Health, Amyris Biotechnologies and sanofi-aventis Announce
Development Agreement for Semisynthetic Artemisinin |
| March 3 |
BioWa Announces Expansion of License Agreement with Genentech for
BioWa's POTELLIGENT Technology |
| March 3 |
Barr Announces Favorable Ruling in Yasmin Patent Challenge |
| March 4 |
StemCells, Inc. Terminates Its Discussions to Acquire Progenitor
Cell Therapy, LLC |
| March 4 |
Court Decides Against Bayer’s Yasmin Patent |
| March 4 |
Allergan Comments on the United States Department of Justice
Subpoena for the Production of Documents Relating to Promotional
Practices of Botox for Therapeutic Uses |
| March 4 |
PsychoGenics and Dainippon Sumitomo Pharma Sign Drug Discovery
Agreement |
| March 4 |
New Technique Involving Roche's LightCycler 480 Instrument Enables
Efficient and Economic Studies on RNA Editing |
| March 4 |
Senate President Announces Major Legislation to Advance
Massachusetts Health Care Reform |
| March 4 |
Astellas to Move Clinical Development Base to U.S. |
| March 4 |
Provectus Pharmaceuticals Receives US Patent Allowance to Provide
Further Protection for Novel Photodynamic Drug PH-12 |
| March 4 |
Medwatch: Tamiflu (oseltamivir phosphate) |
| March 4 |
Breast Cancer Risk Lingered Years after Women Discontinued
Estrogen-Progestin Therapy, Stanford Researcher Says |
| March 4 |
WHI Findings Published in JAMA Do Not Affect Clinical Guidance for
the Appropriate Use of Hormone Therapy |
| March 5 |
Pfizer Presents New Opportunities for Global Growth |
| March 5 |
Medicure Announces Corporate Restructuring |
| March 5 |
PDL BioPharma Ends Sale Process for Company and Restructures to
Focus on Antibody Discovery and Development |
| March 6 |
Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4
Humanized Monoclonal Antibody |
| March 6 |
IMPAX Comments on Lawsuit Related to Generic Version of Detrol LA |
| March 6 |
Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4
Humanized Monoclonal Antibody |
| March 6 |
IMPAX Comments on Lawsuit Related to Generic Version of Detrol LA |
| March 6 |
GSK Statement on MHRA Investigation |
| March 6 |
GSK Investigation Concludes |
| March 6 |
Sensor Necklace Aims to Increase Drug Compliance |
| March 6 |
FDA Updates Safety Information for Long Acting Beta Agonists |
| March 6 |
Mental Health Parity Laudable, But House Legislation Would Put
Medicaid Patients at Risk, Lilly Says |
| March 6 |
PhRMA Statement on Mental Health Parity Legislation |
| March 6 |
Celgene and Pharmion Announce Shareholder Vote in Favor of
Acquisition of Pharmion |
| March 6 |
Kennedy, Ramstad Announce Historic Passage of Paul Wellstone Mental
Health Parity Bill |
| March 6 |
FDA Warns Companies Importing and Marketing Drugs Over the Internet
that Fraudulently Claim to Prevent and Treat STDs |
| March 6 |
Marcadia Biotech, Inc. and Merck & Co., Inc. Enter Strategic
Collaboration |
| March 6 |
Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts |
| March 7 |
Abbott to Collaborate With Genentech, Roche and OSI on Molecular
Test for Lung Cancer Therapy Response |
| March 7 |
Genta Announces Licensing Agreement for Worldwide Development and
Commercialization of a Leading Oral Taxane, Tesetaxel |
| March 7 |
Alkermes Provides Update on Inhaled Insulin Program |
| March 7 |
Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex by
Generic Manufacturer Teva |
| March 7 |
AVANT Announces Completed Merger with Celldex and 1-for-12 Reverse
Stock Split |
| March 10 |
Lilly Announces Termination of AIR Insulin Program |
| March 10 |
Immunicon Corporation Announces Corporate Restructuring |
| March 10 |
Cerimon to Conduct a Proof of Concept Study for Basiliximab for
Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation
of the Eye |
| March 10 |
Amgen Announces Update to U.S. Prescribing Information for Aranesp
and Epogen |
| March 10 |
Conclusion of Co-Development and Co-Marketing Agreement on Z-338
for Functional Dyspepsia in Japan with Astellas Pharma Inc. |
| March 10 |
Curis Announces Conclusion of Hedgehog Agonist Collaboration with
Wyeth |
| March 10 |
A Successful 2007 Paves the Way for Future of Nycomed |
| March 10 |
Tongjitang Receives Proposal to Acquire All Outstanding Shares of
the Company |
| March 10 |
Hagens Berman: Eleven Defendants Settle in Average Wholesale Price
Litigation |
| March 11 |
Cytogen Announces Definitive Merger Agreement with EUSA PHARMA for
$0.62 per Share in Cash |
| March 11 |
Totality of Available Data Reaffirms Procrit (Epoetin alfa) Is Safe
and Effective When Used Appropriately as Labeled to Treat
Chemotherapy-Induced Anemia |
| March 11 |
OmniLytics Enters Collaboration with Elanco |
| March 11 |
FDA Names Permanent Director for Center for Drug Evaluation and
Research |
| March 11 |
Congresswoman Schwartz Calls on EPA to Establish a National
Taskforce to Investigate Pharmaceuticals in America’s Water
Supply |
| March 11 |
Pipex Pharmaceuticals Announces Cost Reduction Measures |
| March 11 |
Microbicide Developer Receives License for Novel HIV Microbicide
Candidate From Merck & Co., Inc. |
| March 11 |
Pfizer's Waxman to Leave |
| March 11 |
U.S. Patent Office Upholds Two Additional Human Embryonic Stem Cell
Patents in Reexamination Decisions |
| March 12 |
Trial Date Set For Seroquel Patent Litigation |
| March 12 |
FDA approval of Abbott's Simcor marks start of co-promotion with
Solvay |
| March 12 |
IMS Health Reports U.S. Prescription Sales Grew 3.8 Percent in
2007, to $286.5 Billion |
| March 12 |
FDA Agrees to Amend Dendreon's Special Protocol Assessment for
Phase 3 IMPACT Study of Provenge |
| March 12 |
Connecticut AG Blumenthal Sues Eli Lilly For Illegally Marketing
Antipsychotic Drug Zyprexa For Unapproved Uses |
| March 12 |
China Aoxing Pharmaceutical Company Signed Definitive Acquisition
Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company,
Ltd. |
| March 12 |
Memory Pharmaceuticals Refocuses to Advance Development and
Clinical Programs |
| March 12 |
Med Ad News Announces Nominees for the 19th Annual Manny Awards |
| March 12 |
Suven Establishes Second CNS Drug Discovery Collaboration with
Lilly |
| March 12 |
M's Science and Eisai Sign Option Agreement for Sigma Agonist
SA4503 |
| March 12 |
FDA and Tibotec Dear Healthcare Professional Letter Regarding New
Prescribing Information for Prezista (darunavir) |
| March 13 |
FDA MedWatch - Prezista (darunavir)- Reports Of Drug Induced
Hepatitis In Patients Receiving Prezista/Ritonavir |
| March 13 |
FDA MedWatch- Erythropoiesis Stimulating Agents- Studies Indicate
Increased Mortality And More Rapid Tumor Progression In Patients
With Cancer Receiving ESAs |
| March 13 |
Statement from Eli Lilly and Company: Response to Connecticut
Attorney General News Release |
| March 13 |
Immtech Announces Update on Business Operations |
| March 13 |
Eularis Exposes Hidden Barriers to Patient Adherence With New
Pharmaceutical Industry Report |
| March 13 |
Roche NimbleGen and Affymetrix Expand Licensing Agreement |
| March 13 |
Silence Therapeutics and AstraZeneca Announce Collaboration to
Develop Novel Approaches for siRNA Drug Delivery |
| March 14 |
Option to Develop Exelixis Compound Exercised By Genentech |
| March 14 |
Lilly and Transition Therapeutics Announce Licensing and
Collaboration Agreement |
| March 14 |
Sen. Kohl Requests Documents from Schering-Plough Regarding
“49 Plan” Sales Push |
| March 14 |
Genentech Provides Business Update at Annual Investment Community
Meeting |
| March 14 |
Genmab and PDL BioPharma Close Sale of Antibody Manufacturing
Facility |
| March 14 |
Ceragenix Completes Patient Visit Phase of Clinical Trial Study to
Compare Efficacy of EpiCeram to Elidel |
| March 14 |
Bostwick Laboratories Announces Initial Public Offering |
| March 14 |
Ortho Biotech Statement on U.S. Food and Drug Administration
Oncologic Drugs Advisory Committee Vote |
| March 17 |
FDA Takes Next Step in Establishing Overseas Presence |
| March 17 |
Merck Scientists Apply Innovative Research Method to Identify
Changes in Gene Networks Linked to Obesity |
| March 17 |
Statement from Eli Lilly and Company: Response to Today's New York
Times Article, 'Lilly E-Mail Discussed Off-Label Drug Use' |
| March 17 |
Reps. Eshoo, Barton Introduce Pathway for Biosimilars Act |
| March 17 |
FDA Indicates That Genasense Approval in Chronic Lymphocytic
Leukemia Will Require Additional Confirmatory Data |
| March 17 |
Amgen and Wyeth Announce Updates to U.S. Prescribing Information
for Enbrel |
| March 17 |
As Problems Surface, Consumerlab.com and the People’s
Pharmacy Ask FDA to Disclose Differences Between Generic and
Original Drugs |
| March 17 |
Oriola-KD to Enter Growing Russian Pharmaceutical Retail and
Wholesale Markets |
| March 17 |
Dynavax and Merck & Co., Inc. Report Clinical Hold of
Investigational Vaccine Heplisav |
| March 18 |
Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline |
| March 18 |
OSI Pharmaceuticals Announces That the Prior Revocation of Its
European DP-IV Patent Has Been Upheld |
| March 18 |
Baxter's Board of Directors Approves New Share Repurchase
Authorization of $2 Billion |
| March 18 |
Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and
Delist From London Stock Exchange |
| March 18 |
Ingenuity Systems Extends Enterprise-Level Software Agreement With
GlaxoSmithKline |
| March 18 |
MedWatch - Tiotropium (marketed as Spiriva HandiHaler): Ongoing
Safety Review - Possible Increased Risk of Stroke |
| March 19 |
Kosan Restructures Workforce to Focus Resources on Lead Clinical
Programs |
| March 19 |
Former Intermune CEO W. Scott Harkonen Indicted for Wire Fraud and
FDA Violations |
| March 19 |
Merck Serono Launches Cyanokit in Japan |
| March 19 |
Florida, 18 States Sue Abbott Laboratories for Blocking Generic
Prescription Competition |
| March 19 |
Alkermes Announces Restructuring |
| March 19 |
Cenix BioScience Signs Framework Research Agreement with
AstraZeneca for RNAi-Based Drug Discovery |
| March 19 |
Galderma Announces HSR Clearance for Its Proposal to Acquire
CollaGenex Pharmaceuticals |
| March 19 |
MedCap Urges Vote Against Proposed VaxGen Merger With Raven
biotechnologies |
| March 20 |
European CHMP Issues Positive Opinion for Viread for the Treatment
of Chronic Hepatitis B |
| March 20 |
Pharming To Receive Negative Opinion On European Marketing
Authorization Application For Rhucin |
| March 20 |
Price of Medicine May Affect Its Efficacy According to Stanford
Business School Research |
| March 20 |
Takeda, Abbott Announce Plans to Conclude TAP Joint Venture |
| March 20 |
EPIX Pharmaceuticals Announces Discontinuation of PRX-00023
Clinical Development Program |
| March 20 |
UCB Advises US-Physicians to Down-Titrate Patients on Neupro In
View of Out-of-Stock Situation in the US |
| March 20 |
Bellwether Industry’s Confidence In UK Slumps –
ABPI/CBI Survey |
| March 20 |
Medicare Announces Expanded Coverage for Warfarin Patients
Monitoring Clotting Time at Home |
| March 21 |
Federal Court of Appeal in Canada Upholds Lipitor Enantiomer
Patent, Decision Prevents Launch of Generic Product by Ranbaxy
until 2010 |
| March 21 |
American Health Packaging Announces a Recall of Approximately 1,400
Units of Heparin Sodium Vial Products as Part of Broader Baxter
Recall |
| March 21 |
EMEA Concludes New Advice to Doctors and Patients for Tysabri
(natalizumab) Needed |
| March 21 |
EMEA Recommends New Contraindication for Velcade (bortezomib) |
| March 21 |
Opexa Therapeutics Announces Retirement of CEO David McWilliams |
| March 24 |
Free Drug Samples May Burden Patients' Pockets |
| March 24 |
CytRx Submits Response to FDA Related to Clinical Program with
Arimoclomol in ALS |
| March 24 |
MedWatch - B. Braun Heparin Sodium Injection Solutions - Recall due
to heparin-like contaminant |
| March 24 |
STG Media Corp. Combines Forces with Internet Solutions Provider
Salient Digital, Inc. to Form STG Interactive |
| March 24 |
Biovail Reaches Settlement With SEC, Provides Update On OSC
Investigation |
| March 24 |
R&D Spending by U.S. Biopharmaceutical Companies Reaches Record
$58.8 Billion in 2007 |
| March 24 |
Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in
Average Wholesale Price Litigation |
| March 24 |
R&D Spending by U.S. Biopharmaceutical Companies Reaches Record
$58.8 Billion in 2007 |
| March 25 |
Jama Editor-in-chief Comments on Pfizer Lawsuit |
| March 25 |
Sonus Pharmaceuticals Refines Strategic Initiatives |
| March 25 |
Drug Alerts Sent Instantly to U.S. Doctors via Email on New
National Network |
| March 25 |
Health Care Services M&A Posts Second-Highest Dollar Level in
2007, According to Irving Levin Associates, Inc. |
| March 25 |
Shire plc: IFRS Results for the Year Ending December 31, 2007 |
| March 26 |
Bayer Schering Pharma Starts New Campaign - Restore the Man |
| March 26 |
State of Alaska and Eli Lilly and Company Reach Agreement to Settle
Zyprexa Lawsuit |
| March 26 |
Plastic Surgery Procedures Maintain Steady Growth in 2007 |
| March 26 |
Evotec's Registration Statement in Connection With its Proposed
Acquisition of Renovis Declared Effective |
| March 26 |
Surveys Find Key Changes in the Role of the Pharmaceutical CFO |
| March 26 |
FDA Makes Recommendations on Medical Devices That Treat Blocked
Heart Arteries |
| March 27 |
FDA Sends Warning Letter to King Pharmaceuticals Over Avinza File
Card |
| March 27 |
FDA Deadlines May Compromise Drug Safety by Rushing Approval |
| March 27 |
Pfizer Clears U.S. Antitrust Review for Acquisition of All
Outstanding Shares of Encysive Pharmaceuticals Inc. |
| March 27 |
Aida Acquires High-Level Research Institute in China |
| March 27 |
Progen Restructures Manufacturing and Drug Discovery Divisions |
| March 27 |
Pegintron Plus Weight-Based Rebetol Resulted in Higher SVR Than
Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C |
| March 27 |
FDA MedWatch- Singulair (montelukast)- Possible Association Between
Use Of Singulair And Behavior/Mood Changes, Suicidality, And
Suicide |
| March 27 |
Phoenix Healthcare Reports on Cholesterol Patients' Reactions to
Publicity and Press Stories |
| March 27 |
Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing
Allegations Involving Abilify |
| March 27 |
FDA MedWatch- Regranex (becaplermin) Gel- Study Data Suggests
Possible Increased Risk Of Death From Cancer In Diabetic Patients
Using The Product |
| March 27 |
FDA MedWatch- Ziagen (abacavir) and Videx (Didanosine)- Study Date
Indicates A Higher Risk of Heart Attack In Patients Infected With
HIV-1 Taking Ziagen Or Videx |
| March 28 |
FDA issues a Communication about an Ongoing Safety Review Regranex
(becaplermin) |
| March 28 |
VaxGen and Raven Terminate Merger Agreement |
| March 28 |
Otsuka to Pay More than $4 Million to Resolve off-label Marketing
Allegations Involving Abilify |
| March 28 |
Discontinuation of Development of TAK-475, a Compound for Treatment
of Hypercholesterolemia |
| March 28 |
Medicines Australia Sets World-First in Transparency |
| March 31 |
Teva to Acquire Bentley Pharmaceuticals |
| March 31 |
Verispan Reports: Physicians Prefer Merck's ePromotion Activities |
| March 31 |
Naglazyme Approved by Japanese Ministry of Health |
| March 31 |
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor
Patent |
